FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2110966639> ?p ?o ?g. }

• W2110966639 endingPage "192" @default.
• W2110966639 startingPage "185" @default.
• W2110966639 abstract "Survival for glioblastoma (GBM) patients with an unmethyated MGMT promoter in their tumor is generally worse than methylated MGMT tumors, as temozolomide (TMZ) response is limited. How to better treat patients with unmethylated MGMT is unknown. We performed a trial combining erlotinib and bevacizumab in unmethylated GBM patients after completion of radiation (RT) and TMZ. GBM patients with an unmethylated MGMT promoter were trial eligible. Patient received standard RT (60 Gy) and TMZ (75 mg/m2 × 6 weeks) after surgical resection of their tumor. After completion of RT they started erlotinib 150 mg daily and bevacizumab 10 mg/kg every 2 weeks until progression. Imaging evaluations occurred every 8 weeks. The primary endpoint was overall survival. Of the 48 unmethylated patients enrolled, 46 were evaluable (29 men and 17 women); median age was 55.5 years (29-75) and median KPS was 90 (70-100). All patients completed RT with TMZ. The median number of cycles (1 cycle was 4 weeks) was 8 (2-47). Forty-one patients either progressed or died with a median progression free survival of 9.2 months. At a follow up of 33 months the median overall survival was 13.2 months. There were no unexpected toxicities and most observed toxicities were categorized as CTC grade 1 or 2. The combination of erlotinib and bevacizumab is tolerable but did not meet our primary endpoint of increasing survival. Importantly, more trials are needed to find better therapies for GBM patients with an unmethylated MGMT promoter." @default.
• W2110966639 created "2016-06-24" @default.
• W2110966639 creator A5000904692 @default.
• W2110966639 creator A5006853372 @default.
• W2110966639 creator A5010077225 @default.
• W2110966639 creator A5011967515 @default.
• W2110966639 creator A5013054218 @default.
• W2110966639 creator A5019360674 @default.
• W2110966639 creator A5020238544 @default.
• W2110966639 creator A5028023803 @default.
• W2110966639 creator A5029952866 @default.
• W2110966639 creator A5037535298 @default.
• W2110966639 creator A5041824343 @default.
• W2110966639 creator A5046338327 @default.
• W2110966639 creator A5055183757 @default.
• W2110966639 creator A5056029006 @default.
• W2110966639 creator A5059298173 @default.
• W2110966639 creator A5062153042 @default.
• W2110966639 creator A5063290790 @default.
• W2110966639 creator A5064593201 @default.
• W2110966639 creator A5064627876 @default.
• W2110966639 creator A5068495908 @default.
• W2110966639 creator A5083697768 @default.
• W2110966639 creator A5087016134 @default.
• W2110966639 creator A5087112179 @default.
• W2110966639 date "2015-10-17" @default.
• W2110966639 modified "2023-10-16" @default.
• W2110966639 title "A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients" @default.
• W2110966639 cites W1972684885 @default.
• W2110966639 cites W1978235312 @default.
• W2110966639 cites W1999476677 @default.
• W2110966639 cites W1999601388 @default.
• W2110966639 cites W2025183726 @default.
• W2110966639 cites W2038657036 @default.
• W2110966639 cites W2040114308 @default.
• W2110966639 cites W2067162187 @default.
• W2110966639 cites W2068220280 @default.
• W2110966639 cites W2070705072 @default.
• W2110966639 cites W2086216067 @default.
• W2110966639 cites W2096287682 @default.
• W2110966639 cites W2104743043 @default.
• W2110966639 cites W2104761954 @default.
• W2110966639 cites W2105100844 @default.
• W2110966639 cites W2105932257 @default.
• W2110966639 cites W2106871559 @default.
• W2110966639 cites W2113818271 @default.
• W2110966639 cites W2117941094 @default.
• W2110966639 cites W2124736921 @default.
• W2110966639 cites W2125887187 @default.
• W2110966639 cites W2132697290 @default.
• W2110966639 cites W2135298618 @default.
• W2110966639 cites W2135947790 @default.
• W2110966639 cites W2145616602 @default.
• W2110966639 cites W2150442444 @default.
• W2110966639 cites W2154670277 @default.
• W2110966639 cites W2156330848 @default.
• W2110966639 cites W2158681922 @default.
• W2110966639 cites W2160137787 @default.
• W2110966639 cites W2160959204 @default.
• W2110966639 cites W2161190434 @default.
• W2110966639 cites W2165871546 @default.
• W2110966639 cites W2168796485 @default.
• W2110966639 cites W2170367762 @default.
• W2110966639 cites W2399370803 @default.
• W2110966639 cites W2492882271 @default.
• W2110966639 cites W4249740696 @default.
• W2110966639 doi "https://doi.org/10.1007/s11060-015-1958-z" @default.
• W2110966639 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4826294" @default.
• W2110966639 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26476729" @default.
• W2110966639 hasPublicationYear "2015" @default.
• W2110966639 type Work @default.
• W2110966639 sameAs 2110966639 @default.
• W2110966639 citedByCount "57" @default.
• W2110966639 countsByYear W21109666392016 @default.
• W2110966639 countsByYear W21109666392017 @default.
• W2110966639 countsByYear W21109666392018 @default.
• W2110966639 countsByYear W21109666392019 @default.
• W2110966639 countsByYear W21109666392020 @default.
• W2110966639 countsByYear W21109666392021 @default.
• W2110966639 countsByYear W21109666392022 @default.
• W2110966639 countsByYear W21109666392023 @default.
• W2110966639 crossrefType "journal-article" @default.
• W2110966639 hasAuthorship W2110966639A5000904692 @default.
• W2110966639 hasAuthorship W2110966639A5006853372 @default.
• W2110966639 hasAuthorship W2110966639A5010077225 @default.
• W2110966639 hasAuthorship W2110966639A5011967515 @default.
• W2110966639 hasAuthorship W2110966639A5013054218 @default.
• W2110966639 hasAuthorship W2110966639A5019360674 @default.
• W2110966639 hasAuthorship W2110966639A5020238544 @default.
• W2110966639 hasAuthorship W2110966639A5028023803 @default.
• W2110966639 hasAuthorship W2110966639A5029952866 @default.
• W2110966639 hasAuthorship W2110966639A5037535298 @default.
• W2110966639 hasAuthorship W2110966639A5041824343 @default.
• W2110966639 hasAuthorship W2110966639A5046338327 @default.
• W2110966639 hasAuthorship W2110966639A5055183757 @default.
• W2110966639 hasAuthorship W2110966639A5056029006 @default.
• W2110966639 hasAuthorship W2110966639A5059298173 @default.
• W2110966639 hasAuthorship W2110966639A5062153042 @default.

• next